News Hub

Real-time financial, economic, and global news with market-focused context and analysis.

Coverage spans equities, macroeconomic data, commodities, currencies, technology, politics, and global events—paired with analysis that highlights why each development matters for traders and investors. From breaking headlines to hourly market snapshots and in-depth articles, the News Hub is designed to help you stay informed, oriented, and ahead of market-moving events.

  • No significant economic data or central bank announcements released in the past hour.
  • Global equity markets showed limited headline-driven movement during the hour.
  • No major geopolitical incidents reported that would affect commodity or FX markets.
  • Corporate news flow was light with no large M&A or earnings surprises announced.
  • Treasury yields and major FX pairs remained range-bound absent fresh catalysts.

Latest Articles

Diginex (NASDAQ: DGNX) Launches Enhanced End-to-End Supply Chain Platform Targeting $7+ Billion Market by 2029, Growing at 29% CAGR

Diginex (NASDAQ: DGNX) Launches Enhanced End-to-End Supply Chain Platform Targeting $7+ Billion Market by 2029, Growing at 29% CAGR

Diginex Limited (NASDAQ: DGNX) announced the launch of an enhanced end-to-end supply chain due diligence platform designed to provide companies with comprehensive visibility across multiple supplier tiers. This platform aims to help firms identify and mitigate risks, lower operating costs, reduce litigation exposures, and comply with evolving regul…

Weight Watchers and Google Health Enterprise Launch New Collaboration to Enhance Engagement and Outcomes in Weight Health Programs

Weight Watchers and Google Health Enterprise Launch New Collaboration to Enhance Engagement and Outcomes in Weight Health Programs

WW International, Inc. announces a strategic collaboration with Google Health Enterprise to enhance its weight management program through integration with Google's Fitbit Air wearable and AI-powered insights. The partnership aims to increase engagement and improve outcomes by offering personalized tracking of activity, sleep, and health signals to …

Provident Bank Survey: 7 in 10 Americans Are Rethinking Higher Education, and Nearly 1 in 3 Are Eyeing the Alternatives

Provident Bank Survey: 7 in 10 Americans Are Rethinking Higher Education, and Nearly 1 in 3 Are Eyeing the Alternatives

Provident Bank's 2026 Higher Education Survey shows nearly 70% of Americans are rethinking the financial value of traditional higher education amid rising costs, with increasing consideration for trade and technical schools as viable alternatives. The survey highlights gaps in education savings and a significant opportunity for banks to provide bet…

NewAmsterdam Pharma Doses First Participant in Phase 2b SPINOZA Trial Evaluating Obicetrapib in Preclinical Alzheimer’s Disease

NewAmsterdam Pharma Doses First Participant in Phase 2b SPINOZA Trial Evaluating Obicetrapib in Preclinical Alzheimer’s Disease

NewAmsterdam Pharma has dosed the first participant in its Phase 2b SPINOZA clinical trial evaluating obicetrapib, a novel oral CETP inhibitor, in adults with biomarker evidence of preclinical Alzheimer's disease. The trial involves approximately 400 patients with specific ApoE genotypes and aims to assess changes in Alzheimer's disease biomarkers …

Phathom Pharmaceuticals Announces Initiation of Registrational Phase 3 Study of VOQUEZNA® (vonoprazan) for As-Needed Treatment of Non-Erosive GERD

Phathom Pharmaceuticals Announces Initiation of Registrational Phase 3 Study of VOQUEZNA® (vonoprazan) for As-Needed Treatment of Non-Erosive GERD

Phathom Pharmaceuticals announced the initiation of a registrational Phase 3 study (pHalcon-NERD-302) to evaluate VOQUEZNA (vonoprazan) as an as-needed treatment for Non-Erosive GERD (NERD). Building on positive Phase 2 data, this study aims to assess the efficacy and safety of VOQUEZNA in providing rapid and sustained relief of heartburn episodes.…

Tokyo Lifestyle Co., Ltd. Strengthens Capital Structure Through Cash Investment and Debt-to-Equity Conversion

Tokyo Lifestyle Co., Ltd. Strengthens Capital Structure Through Cash Investment and Debt-to-Equity Conversion

Tokyo Lifestyle Co., Ltd. announced two key equity transactions approved by its board aimed at strengthening the company's capital structure. The Representative Director made a direct cash investment of approximately US$0.38 million, while an affiliated entity converted JPY510 million (approx. US$3.32 million) of outstanding shareholder-related deb…

SaverOne Awarded U.S. Patent for Automated Sensor Fusion Calibration and Maintenance: Strengthening its IP Protection as Fleet Deployments Scale

SaverOne Awarded U.S. Patent for Automated Sensor Fusion Calibration and Maintenance: Strengthening its IP Protection as Fleet Deployments Scale

SaverOne has been awarded a new U.S. patent for its advanced sensor fusion-based calibration and maintenance technology for its Phone Location Unit (PLU). This innovation allows the system to self-calibrate and maintain full operational accuracy over the vehicle's lifecycle, supporting efficient remote servicing at fleet scale. The patent strengthe…

Nasus Pharma Announces Enrollment and Dosing of First Patient in Phase 1 Study of NS003 Intranasal Formulation of Ondansetron

Nasus Pharma Announces Enrollment and Dosing of First Patient in Phase 1 Study of NS003 Intranasal Formulation of Ondansetron

Nasus Pharma has enrolled and dosed its first patient in the Phase 1 pharmacokinetic study of NS003, an intranasal powder formulation of ondansetron aimed at treating chemotherapy-induced and post-operative nausea and vomiting. Preclinical data showed NS003's pharmacokinetic profile comparable to IV ondansetron with a favorable safety profile. The …

Dianthus Therapeutics Highlights Claseprubart Data Presentations Planned for 2026 AANEM Annual Meeting

Dianthus Therapeutics Highlights Claseprubart Data Presentations Planned for 2026 AANEM Annual Meeting

Dianthus Therapeutics announced scheduled oral and poster presentations at the 2026 American Association of Neuromuscular and Electrodiagnostic Medicine (AANEM) Annual Meeting, showcasing encouraging Phase 2 and Phase 3 data for claseprubart, their investigational monoclonal antibody targeting autoimmune diseases such as generalized myasthenia grav…

One and One Green Technologies Reports First Half 2026 Results

One and One Green Technologies Reports First Half 2026 Results

One and One Green Technologies, Inc. announced financial results for the first half of 2026, reporting an 18.7% increase in revenue to $33.4 million and a 17.4% rise in net income to $4.5 million. Growth was fueled by a 39% increase in copper alloy ingot revenue due to stronger demand in Asia-Pacific and capacity reallocation, despite a temporary s…

Microchip Expands Single Pair Ethernet Portfolio with New 10BASE‑T1S Devices Enabling Scalable Edge Connectivity

Microchip Expands Single Pair Ethernet Portfolio with New 10BASE‑T1S Devices Enabling Scalable Edge Connectivity

Microchip Technology expands its Single Pair Ethernet portfolio with the launch of LAN8679 and LAN8680 10BASE-T1S PMD transceivers and the LAN8660X/1X/2X integrated endpoint family. These devices enable flexible, space-efficient, and reliable Ethernet connectivity for next-generation zonal architectures across automotive, industrial, robotics, aero…

TMC Announces Appointment of Liam Mallon, Former President of ExxonMobil Upstream, to its Board of Directors

TMC Announces Appointment of Liam Mallon, Former President of ExxonMobil Upstream, to its Board of Directors

The Metals Company has appointed Liam Mallon, ex-President of ExxonMobil Upstream, to its Board of Directors. Mallon's extensive experience in offshore energy projects and capital deployment will support TMC as it advances toward launching the world's first commercial-scale deep seabed mineral operations under U.S. regulatory frameworks. His leader…

Corbus Pharmaceuticals Announces First Patient Dosed in TEMPO-1 Registrational Study of CRB-701 in Patients with 2L+ Oropharyngeal Cancer

Corbus Pharmaceuticals Announces First Patient Dosed in TEMPO-1 Registrational Study of CRB-701 in Patients with 2L+ Oropharyngeal Cancer

Corbus Pharmaceuticals has dosed the first patient in its TEMPO-1 registrational study evaluating CRB-701, a novel Nectin-4 targeted antibody drug conjugate, for treatment of second-line and beyond oropharyngeal squamous cell carcinoma (OPSCC). The Phase 3 randomized controlled trial aims to confirm the drug's efficacy and safety compared to curren…

Tectonic Therapeutic Announces Favorable Phase 1 Safety, Tolerability and PK Results for TX2100, a Novel Approach for the Treatment of Hereditary Hemorrhagic Telangiectasia (HHT)

Tectonic Therapeutic Announces Favorable Phase 1 Safety, Tolerability and PK Results for TX2100, a Novel Approach for the Treatment of Hereditary Hemorrhagic Telangiectasia (HHT)

Tectonic Therapeutic announced favorable safety, tolerability, and pharmacokinetic results from its Phase 1a clinical trial of TX2100, a novel APJ receptor antagonist antibody for treating Hereditary Hemorrhagic Telangiectasia (HHT). The FDA granted Fast Track designation for TX2100 and cleared the IND application for a Phase 1b trial in HHT patien…

Brunswick Corporation Announces Senior Leadership Appointments

Brunswick Corporation Announces Senior Leadership Appointments

Brunswick Corporation has announced the appointment of Will Sangster as EVP and President of Navico Group, Karly Yuds as SVP and President of Business Acceleration, and Marco Bracalente as Chief Technology Officer. These senior leadership changes follow the recent CEO and Board Chair transitions effective January 1, 2027. The appointments reflect B…